Novo Nordisk A/S (NVO) Stock Price & Analysis
Novo Nordisk A/S (NVO) closed at USD 39.43 on Thursday, October 22, 2026, up 0.95% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 39.43; the Oct 22, 2026 session ranged USD 39.24–39.77 on volume of 8,533,145 shares. Market capitalization is —, with a 52-week range of USD 35.12–64.16 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:27 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NVO.md
Key facts (NVO)
- 4 of 80 tracked superinvestors hold NVO (13F, Q2 2026): 0 new, 2 added, 1 reduced, 1 unchanged.
- Total return with dividends: 1Y -22.2% vs S&P 500 +14.9%; 5Y -16.6% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD 4.62, revenue estimate $73.8B.
Superinvestors (SEC 13F-HR, Q2 2026) (NVO)
4 of 80 tracked investors hold NVO. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Thomas Gayner | Markel Group | 1.05% | $138M | Unchanged |
| Sarah Ketterer | Causeway Capital Management | 0.87% | $80.4M | Added +42.9% |
| Lee Ainslie | Maverick Capital | 0.72% | $79.3M | Reduced -20.5% |
| Dodge & Cox Funds | Dodge & Cox | 0.51% | $978M | Added +5.5% |
Analysts (NVO)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | BMO Capital | Target lowered | Market Perform | $47 → $40 |
| 2026-09-11 | Morgan Stanley | Downgrade | Equal-Weight → Underweight | $40 |
Total return (dividends reinvested) (NVO)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -22.2% | -16.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -22.3% | -3.5% |
| Volatility (annualized) | 46.5% | 42.2% |
| Max drawdown | -43.7% (Jan 2026→Mar 2026) | -74.0% (Jun 2024→Mar 2026) |
Companies that name NVO in their SEC reports
| Relationship to NVO | Company | Filing | Sentence |
|---|---|---|---|
| competitor | iBio, Inc. (IBIO) | 10-K Aug 28, 2026 | “Our most significant competitors, among others, are fully integrated pharmaceutical companies such as Eli Lilly and Company, Novo Nordisk A/S, Amgen Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Novartis AG, MedImmune, LLC (a wholly owned subsidiary of AstraZeneca PLC), Johnson & Johnson, Pfizer Inc., Merck KGaA and Sanofi SA, and more established biotechnology companies such as Genentech, Inc. (a member …” |
| partner | Evotec SE (EVO) | 20-F Apr 8, 2026 | “Based on the strength of our molecular CKD patient database, we have built four partnerships in kidney diseases in the last almost ten years with prominent pharmaceutical companies such as Bayer, Vifor (now "CSL Vifor"), Novo Nordisk, Eli Lilly, and Chinook (now a Novartis company).” |
| competitor | Inventiva S.A. (IVA) | 20-F Apr 8, 2026 | “Furthermore, we face strong competition for enrollment from competitors who have received marketing authorization, such as Madrigal with Rezdiffra, and Novo Nordisk with Wegovy, and others who are conducting ongoing clinical trials evaluating their drug candidates in MASH, such as Boehringer Ingelheim, 89Bio/Roche, Akero Therapeutics (a subsidiary of Novo Nordisk), Boston Pharmaceuticals, GSK, and Eli Lilly and Co…” |
| partner | Innate Pharma SA (IPHA) | 20-F Apr 1, 2026 | “For example, Innate depends on its license agreement with Novo Nordisk A/S for the development and commercialization of monalizumab.” |
| competitor | MANGOCEUTICALS, INC. (MGRX) | 10-K Apr 1, 2026 | “With our Mango SLIM product, we compete against the much larger pharmaceutical company Novo Nordisk., which offers the branded glucagon-like” |
| partner | OMEROS CORP (OMER) | 10-K Mar 31, 2026 | “● our expectations relating to the Asset Purchase and License Agreement (the "APLA"), by and between Omeros Corporation and Novo Nordisk Health Care AG ("Novo Nordisk"), including Novo Nordisk's anticipated development plans for zaltenibart, anticipated outcomes of such plans and the amounts potentially payable to us under the terms of the APLA;” |
| competitor | Alaunos Therapeutics, Inc. (TCRT) | 10-K Mar 31, 2026 | “Key competitors in the obesity space include (but are not limited to) companies such as Novo Nordisk, Eli Lilly, Amgen, Pfizer, Viking Therapeutics, Structure Therapeutics, and others.” |
| competitor | Galmed Pharmaceuticals Ltd. (EOCN) | 20-F Mar 31, 2026 | “main competitors include Novo Nordisk with respect to Wegovy, which has typically been known for treating weight loss and diabetes and” |
| competitor | Rani Therapeutics Holdings, Inc. (RANI) | 10-K Mar 26, 2026 | “We face competition from current and future (generic and biosimilars) manufacturers of subcutaneous and IV injectable versions of our product candidates, such as AbbVie Inc., Eli Lilly and Company, Janssen Biotech, Inc., as well as obesity treatments from Eli Lilly and Company, Novo Nordisk A/S, ProGen and others.” |
| competitor | Vivani Medical, Inc. (VANI) | 10-K Mar 26, 2026 | “Some of our competitors in the GLP-1 receptor agonist drug class include companies such as Novo Nordisk, AstraZeneca, and Eli Lilly.” |
| competitor | Monte Rosa Therapeutics, Inc. (GLUE) | 10-K Mar 17, 2026 | “In addition to competition we face in developing TPD or MGD therapeutics, we will also face competition in the indications we expect to pursue with our GSPT1, NEK7, and CCNE1/CDK2 programs, including, but not limited to, programs from AstraZeneca, Roche, Novo Nordisk, Novartis, Ventyx Biosciences, BioAge Labs, NodThera, Pfizer, Merck, BeOne Medicines, and Incyte Corporation.” |
| partner | Korro Bio, Inc. (KRRO) | 10-K Mar 12, 2026 | “our collaboration arrangement with Novo Nordisk A/S, or Novo Nordisk, including effects of the recent pause, and any future collaboration or licensing arrangements;” |
| competitor | Sagimet Biosciences Inc. (SGMT) | 10-K Mar 11, 2026 | “Our competitors include multinational pharmaceutical companies, specialized biotechnology companies and universities and other research institutions, including Altimmune, Inc., AstraZeneca, Boehringer Ingelheim and Zealand Pharma, Eli Lilly and Company, Galmed Pharmaceuticals Ltd., Gilead Sciences, Inc., GSK plc (acquired Boston Pharmaceuticals in 2025), Inventiva S.A., Madrigal, Merck & Co., Inc., Novo Nordisk A/…” |
| partner | vTv Therapeutics Inc. (VTVT) | 10-K Mar 10, 2026 | “In February 2007, we entered into an Agreement Concerning Glucokinase Activator Project with Novo Nordisk A/S (the "Novo License Agreement") whereby we obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use, and commercialize products for the prevention, treatment, control, mitigation, or palliation o…” |
| competitor | Skye Bioscience, Inc. (SKYE) | 10-K Mar 10, 2026 | “In particular, there is intense competition in the obesity and overweight field, especially with the advent of GLP-1 RAs, such as Wegovy, marketed by Novo Nordisk, and Zepbound, marketed by Eli Lilly.” |
NVO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $4.62 | $4.79 | -3.5% | $73.79B | 3 |
| Next quarter (ends Dec 2026) | $4.31 | $4.67 | -7.7% | $76.16B | 2 |
| Current fiscal year (ends Dec 2026) | $22.39 | $21.86 | +2.4% | $303.47B | 8 |
| Next fiscal year (ends Dec 2027) | $22.89 | $22.02 | +3.9% | $307.69B | 7 |
Key Statistics (as of October 23, 2026 at 09:27 UTC)
| Price | USD 39.43 |
|---|---|
| Change | ▲ 0.95% (up) |
| Previous Close | USD 39.43 |
| Open | USD 39.43 |
| Day Range | USD 39.24 – 39.77 |
| 52-Week Range | USD 35.12 – 64.16 |
| Volume | 8,533,145 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (NVO)
Nexqual's technical model rates NVO "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 09:27 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.17 (neutral) |
| vs SMA50 | Below (USD 42.06) |
| MACD | -0.74 (negative) |
Earnings (NVO)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 4.62 |
| Revenue Estimate | $73.79B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 6.18 vs est 4.98 ▲ beat |
| 2026-03-31 | USD 6.63 vs est 6.96 ▼ miss |
| 2025-12-31 | USD 6.04 vs est 5.9 ▲ beat |
| 2025-09-30 | USD 4.5 vs est 4.24 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Financials & Fundamentals (NVO)
| Total Revenue | $329.43B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +2.10% |
| Gross Margin | +81.99% |
| Operating Margin | +42.54% |
| Profit Margin | +35.35% |
| ROE | +59.81% |
| Debt / Equity | 0.63 |
| Current Ratio | 0.87 |
| Total Cash | $44.98B |
| Total Debt | $140.13B |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Ownership (NVO)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +9.82% |
| Shares Outstanding | 3.34B |
| Float | 3.17B |
| Short % of Float | +1.00% |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Leadership (NVO)
Novo Nordisk A/S is led by Maziar Mike Doustdar B.A., President, CEO & Member of the Management Board, per Nexqual as of October 23, 2026 at 09:27 UTC.
| President, CEO & Member of the Management Board | Maziar Mike Doustdar B.A. |
|---|---|
| Executive VP, CFO & Member of the Management Board | Karsten Munk Knudsen |
| EVP of R & D, Chief Scientific Officer and Member of the Management Board | Martin Holst Lange |
Major Backers & Investors (NVO)
Notable institutional backers of Novo Nordisk A/S include Dodge & Cox Inc., LOOMIS SAYLES & CO L P, Franklin Resources, Inc., according to Nexqual as of October 23, 2026 at 09:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 0.6% |
| LOOMIS SAYLES & CO L P | 0.55% |
| Franklin Resources, Inc. | 0.38% |
| Price (T.Rowe) Associates Inc | 0.35% |
| Morgan Stanley | 0.34% |
| Bank of America Corporation | 0.33% |
| Capital International Investors | 0.29% |
| Folketrygdfondet | 0.28% |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PFE | Pfizer, Inc. | USD 30.42 | ▲ 1.91% |
| GILD | Gilead Sciences, Inc. | USD 157.19 | ▲ 2.36% |
| BMY | Bristol-Myers Squibb Company | USD 63 | ▲ 3.08% |
| AMGN | Amgen Inc. | USD 447.28 | ▲ 2.04% |
| AZN | AstraZeneca PLC | USD 172.57 | ▲ 2.45% |
| GSK | GSK plc | USD 51.21 | ▲ 2.38% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:27 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt